With authoritative coverage of everything from recent discoveries in the field of vascular biology to recent clinical trials and evidence-based treatment strategies, Vascular Medicine, 3rd Edition, is your go-to resource for improving your patients’ cardiovascular health. Part of the Braunwald family of renowned cardiology references, this updated volume integrates a contemporary understanding of vascular biology with a thorough review of clinical vascular diseases, making it an ideal reference for vascular medicine specialists, general cardiologists, interventional cardiologists, vascular surgeons, and interventional radiologists. Incorporates technologic advances in vascular imaging – including ultrasound, MRI, CTA, and catheter-based angiography – along with more than 230 new figures, providing an up-to-date and complete view of the vascular system and vascular diseases. Covers novel antithrombotic therapies for peripheral artery disease and venous thromboemboism, advances in endovascular interventions for aortic aneurysms, and today’s best surgical treatments for vascular diseases. Includes seven new chapters: Pathobiology of Aortic Aneurysms; Pathobiology and Assessment of Cardiovascular Fibrosis; Large Vessel Vasculitis; Medium and Small Vessel Vasculitis; Epidemiology and Prognosis of Venous Thromboembolic Disease; Fibromuscular Dysplasia; and Dermatologic Manifestations of Vascular Disease. Discusses methods for aggressive patient management and disease prevention to ensure minimal risk of further cardiovascular problems. Keeps you current with ACC/AHA and ECC guidelines and the best ways to implement them in clinical practice.

Integrates the understanding of vascular biology with reviews of pathophysiology, diagnosis, and management. This comprehensive and clinically oriented coverage equips you to evaluate patients with a range of vascular diseases, and to implement the appropriate diagnostic and therapeutic strategies available.

Manage cardiovascular problems more effectively with the most comprehensive resource available! A trusted companion to Braunwald's Heart Disease, Cardiovascular Therapeutics, 4th Edition addresses pharmacological, interventional, and surgical management approaches for each type of cardiovascular disease. This practical and clinically focused cardiology reference offers a balanced, complete approach to all of the usual and unusual areas of cardiovascular disease and specific therapies in one concise volume, equipping you to make the best choices for every patient. Consult this title on your favorite e-reader with intuitive search tools and adjustable font sizes. Elsevier eBooks provide instant portable access to your entire library, no matter what device you're using or where you're located. Understand current approaches to treating and managing cardiovascular patients for long-term health, for complex problems, and for unusual cardiac events. Benefit from the substantial experience of Elliott M. Antman, MD, Marc S. Sabatine, MD, and a host of other respected authorities, who provide practical, evidence-based rationales for all of today's clinical therapies. Expand your knowledge beyond pharmacologic interventions with complete coverage of the most effective interventional and device therapies being used today. Easily reference Braunwald's Heart Disease, 9th Edition for further information on topics of interest. Make the best use of the latest genetic and molecular therapies as well as advanced therapies for heart failure. Cut right to the answers you need with an enhanced focus on clinically relevant information and a decreased emphasis on pathophysiology. Stay current with ACC/AHA/ESC guidelines and the best ways to implement them in clinical practice. Get an enhanced visual perspective with an all-new, full-color design throughout.

Authoritative, portable, and up to date, Opie’s Cardiovascular Drugs, 9th Edition, is the definitive reference for quick access to frequently used drugs in all phases of care for cardiac patients. Now a part of the Braunwald family of renowned cardiology references, this compact title provides crucial information in an easily accessible format—ideal for cardiologists, residents, cardiology fellows, medical students, nurses, and other cardiac care providers. Updated to include the latest guidelines and evidence-based implications, it offers clear and concise explanations and pertinent clinical facts for all classes of cardiac drugs, as well as all the latest clinical trial results and evidence for the pharmacologic treatment of heart disease. Uses a new, consistent format for each drug class: overview and guidelines for use, mechanisms of action, differences among drugs in class, data for use, side effects, and drug interactions. Covers key topics such as new ESC and NLA guidelines, advances in lipid-lowering therapy, new diabetes drugs that improve cardiovascular outcomes, obesity drugs and cardiovascular and metabolic effects, drugs targeting inflammation, and combinations of antithrombotic therapies with analysis of risk-benefit. Provides guidance on how to effectively manage comorbid diseases. Contains dozens of unique “Opiegram diagrams that demystify complex mechanisms of action and other drug processes—many updated to reflect current pathologic understanding of mechanisms.

Challenges for the treatment of valvular heart disease include the growing need for effective yet less invasive interventions and therapies to treat these progressive conditions. With the development of potential new treatments, it is crucial for cardiac physicians to be well informed on the pathophysiology, assessment, treatment options and their outcomes of valvular diseases. Written by a highly experienced and internationally recognized group of cardiologists, cardiac surgeons, and researchers, Valvular Heart Disease offers insights into the widely varying hemodynamic effects and clinical course of heart valve conditions, as well as the contemporary management of these conditions. Offering a broad perspective on these diseases, Valvular Heart Disease expands on the recent guidelines developed by the major heart societies in the United State and Europe.